While L-DOPA is the gold-standard treatment for Parkinson's disease, side effects called dyskinesias can develop after long-term treatment. This thesis validated that a novel drug called UWA-101 reduces L-DOPA-induced dyskinesias in the reserpine rat model of Parkinson's disease and expanded upon this model as an inexpensive and rapid screening tool for other antidyskinetic drugs compared to more time-consuming and expensive animal models. For the first time, it was demonstrated that UWA-101 lacks the subjective effects of its parent compound MOMA ("ecstasy") and, with its antidyskinetic effects, may be an effective treatment for dyskinesias in Parkinson's disease.
|Qualification||Doctor of Philosophy|
|Award date||14 Feb 2020|
|Publication status||Unpublished - 2020|